StockNews.com Initiates Coverage on Marinus Pharmaceuticals (NASDAQ:MRNS)

Research analysts at StockNews.com assumed coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research report issued to clients and investors on Saturday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

Several other research analysts also recently commented on the company. Royal Bank of Canada dropped their price target on Marinus Pharmaceuticals from $3.00 to $1.00 and set a “sector perform” rating on the stock in a research report on Friday, October 25th. HC Wainwright reaffirmed a “neutral” rating and set a $2.00 target price on shares of Marinus Pharmaceuticals in a research report on Thursday, November 14th. TD Cowen reissued a “hold” rating on shares of Marinus Pharmaceuticals in a report on Friday, October 25th. Oppenheimer upgraded shares of Marinus Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 price objective on the stock in a report on Monday, September 23rd. Finally, JMP Securities reaffirmed a “market perform” rating on shares of Marinus Pharmaceuticals in a research report on Thursday, October 24th. Nine investment analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $4.79.

Marinus Pharmaceuticals Stock Performance

Marinus Pharmaceuticals stock opened at $0.37 on Friday. Marinus Pharmaceuticals has a 52 week low of $0.22 and a 52 week high of $11.26. The firm has a market capitalization of $20.50 million, a PE ratio of -0.15 and a beta of 1.25. The business’s 50-day simple moving average is $0.39 and its 200-day simple moving average is $1.07.

Institutional Trading of Marinus Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MRNS. JPMorgan Chase & Co. boosted its holdings in Marinus Pharmaceuticals by 1,968.5% during the third quarter. JPMorgan Chase & Co. now owns 133,191 shares of the biopharmaceutical company’s stock valued at $234,000 after purchasing an additional 126,752 shares in the last quarter. Franklin Resources Inc. lifted its position in shares of Marinus Pharmaceuticals by 34.9% during the 3rd quarter. Franklin Resources Inc. now owns 4,713,014 shares of the biopharmaceutical company’s stock worth $8,483,000 after buying an additional 1,219,871 shares during the period. World Investment Advisors LLC acquired a new stake in Marinus Pharmaceuticals in the 3rd quarter valued at $104,000. Jacobs Levy Equity Management Inc. grew its position in Marinus Pharmaceuticals by 39.5% in the third quarter. Jacobs Levy Equity Management Inc. now owns 414,269 shares of the biopharmaceutical company’s stock valued at $729,000 after acquiring an additional 117,255 shares during the period. Finally, Suvretta Capital Management LLC raised its stake in Marinus Pharmaceuticals by 32.8% during the third quarter. Suvretta Capital Management LLC now owns 5,073,913 shares of the biopharmaceutical company’s stock worth $8,930,000 after acquiring an additional 1,253,901 shares in the last quarter. Institutional investors own 98.80% of the company’s stock.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.